Re: Chimeric Antigen Receptor T Cells as Adjuvant Therapy for Unresectable Adenocarcinoma

Eur Urol. 2024 Mar;85(3):304. doi: 10.1016/j.eururo.2023.10.017. Epub 2023 Nov 10.
No abstract available

MeSH terms

  • Adenocarcinoma* / therapy
  • Combined Modality Therapy
  • Humans
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes

Substances

  • Receptors, Chimeric Antigen